Form 4: Singular Genomics Systems CEO Andrew Spaventa Reports Stock Transactions

CEO Andrew Spaventa reports the vesting and gifting of shares, along with adjustments to previously reported holdings.

Summary

• Andrew Spaventa, CEO of Singular Genomics Systems, reported transactions involving the company's common stock and Restricted Stock Units (RSUs) on March 15, 2024.
• Spaventa acquired 14,583 shares of common stock through the settlement of vested RSUs.
• He then gifted these shares to The Andrew K. Spaventa Living Trust dated April 9, 2014.
• An administrative error regarding 2,569 shares held by Axon Holdings, LLC was corrected; these shares were previously reported as distributed but were not.
• Spaventa directly owns 9,766 shares and indirectly owns 4,090,372 shares through The Andrew K. Spaventa Living Trust and 2,569 shares through Axon Holdings, LLC.
• He also holds 175,000 RSUs, which vest in equal quarterly installments from March 15, 2023.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing, so the sentiment is neither positive nor negative.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency into the trading activities of key personnel and their ownership stakes in the company.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders.
• The information disclosed is consistent with regulatory requirements for reporting changes in beneficial ownership.

Related Party Transactions

• The gifting of shares to The Andrew K. Spaventa Living Trust is a related party transaction.

Stakeholder Impact

• The filing provides transparency to shareholders regarding insider transactions.
• The correction of the administrative error ensures accurate reporting of share ownership.

Key Dates